Mild cognitive impairment vs. mild cognitive dysfunctions: validation with a nomothetic network approach

article: Mild cognitive impairment vs . mild cognitive dysfunctions: validation with a nomothetic network approach. Abstract Aim: No studies have examined whether interactions between the apolipoprotein E4 (ApoE4) allele and peripheral biomarkers, hypertension, and type 2 diabetes mellitus (T2DM) may impact the neurocognitive, behavioral, and social dysfunctions in amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease (AD). We aimed to clinically define and biologically validate a subgroup of aMCI subjects who take up an intermediate position between controls and AD patients. age, and education. The OBD index was used to construct three subgroups (normal, medium, and high OBD) with the medium group ( n = 45) showing mild cognitive dysfunctions (MCD) in memory, language, orientation, and ADL. People with MCD show OBD and BIORISK scores that are significantly different from controls and AD. Conclusion: Petersen’s aMCI criteria cannot be validated and should be replaced by the more restrictive, biologically validated MCD class. statistical significance. Two-step cluster analysis was employed to define clusters of patients based on the cognitome and phenome features. Nearest neighbor analysis was employed to classify subjects based on their feature similarities. All statistical analyses were performed using IBM SPSS windows version 25. phenome latent vectors extracted by PLS scores (3k, Euclidian distance, training sample of 70%, and a holdout sample of 30%), and this analysis showed 45.0% misclassifications in both the training and holdout samples with many aMCI subjects being allocated to the normal control class.